US FDA's New Neurology Leadership Likely To Face Two Big Reviews In 2020
Executive Summary
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.